Clinical management of malignant adrenal tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-02

AUTHORS

Daniel Kopf, Peter E. Goretzki, Hendrik Lehnert

ABSTRACT

Malignant primary adrenal tumors are rare forms of cancer with an estimated incidence of two to ten new cases per one million inhabitants per year. The 5-year survival rate for adrenocortical carcinoma is approximately 35%, whereas the 10-year survival rate of malignant pheochromocytoma reaches 40%. Clinical studies support repeated surgery as the mainstay of treatment, either with curative or palliative intention. For adrenocortical carcinoma, adjunctive treatment with oral mitotane leads to well-documented improvement of survival. Rare malignant pheochromocytomas with distant metastases are preferably treated by 131I-MIBG. Chemotherapy is reserved for unresectable tumors without sufficient response to mitotane or 131I-MIBG, respectively. Cisplatin and etoposide as single therapy, or in combination with doxorubicin or etoposide, appear to be effective in adrenocortical carcinoma. Malignant pheochromocytoma may be treated with vincristine, dacarbazine, and cyclophosphamide. Treatment with octreotide is currently being evaluated. Radiotherapy is indicated if unresectable tumor masses cause local symptoms. If symptoms of endocrine activity are not sufficiently controlled by measures aiming at tumor mass reduction, specific inhibitors of hormone synthesis or action are available. Ketoconazole is widely used for adrenocortical carcinoma, and phenoxybenzamine and metyrosine are available for malignant pheochromocytoma. This review provides guidelines for rational disease management based on still scanty clinical evidence. More... »

PAGES

143-155

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s004320000170

DOI

http://dx.doi.org/10.1007/s004320000170

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027963130

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11260859


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenal Cortex Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenal Gland Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenocortical Carcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diagnosis, Differential", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pheochromocytoma", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Otto-von-Guericke University Magdeburg", 
          "id": "https://www.grid.ac/institutes/grid.5807.a", 
          "name": [
            "Department of Endocrinology and Metabolism, Otto von Guericke University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany Tel.: +49-391-6715445; Fax: +49-391-6715448 e-mail: hendrik.lehnert@medizin.uni-magdeburg.de, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kopf", 
        "givenName": "Daniel", 
        "id": "sg:person.01301252336.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301252336.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Heinrich Heine University D\u00fcsseldorf", 
          "id": "https://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Surgery, Heinrich Heine University D\u00fcsseldorf, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goretzki", 
        "givenName": "Peter E.", 
        "id": "sg:person.01076650120.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076650120.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Otto-von-Guericke University Magdeburg", 
          "id": "https://www.grid.ac/institutes/grid.5807.a", 
          "name": [
            "Department of Endocrinology and Metabolism, Otto von Guericke University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany Tel.: +49-391-6715445; Fax: +49-391-6715448 e-mail: hendrik.lehnert@medizin.uni-magdeburg.de, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lehnert", 
        "givenName": "Hendrik", 
        "id": "sg:person.0622641625.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622641625.90"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2001-02", 
    "datePublishedReg": "2001-02-01", 
    "description": "Malignant primary adrenal tumors are rare forms of cancer with an estimated incidence of two to ten new cases per one million inhabitants per year. The 5-year survival rate for adrenocortical carcinoma is approximately 35%, whereas the 10-year survival rate of malignant pheochromocytoma reaches 40%. Clinical studies support repeated surgery as the mainstay of treatment, either with curative or palliative intention. For adrenocortical carcinoma, adjunctive treatment with oral mitotane leads to well-documented improvement of survival. Rare malignant pheochromocytomas with distant metastases are preferably treated by 131I-MIBG. Chemotherapy is reserved for unresectable tumors without sufficient response to mitotane or 131I-MIBG, respectively. Cisplatin and etoposide as single therapy, or in combination with doxorubicin or etoposide, appear to be effective in adrenocortical carcinoma. Malignant pheochromocytoma may be treated with vincristine, dacarbazine, and cyclophosphamide. Treatment with octreotide is currently being evaluated. Radiotherapy is indicated if unresectable tumor masses cause local symptoms. If symptoms of endocrine activity are not sufficiently controlled by measures aiming at tumor mass reduction, specific inhibitors of hormone synthesis or action are available. Ketoconazole is widely used for adrenocortical carcinoma, and phenoxybenzamine and metyrosine are available for malignant pheochromocytoma. This review provides guidelines for rational disease management based on still scanty clinical evidence.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s004320000170", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "127"
      }
    ], 
    "name": "Clinical management of malignant adrenal tumors", 
    "pagination": "143-155", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8534fbcad3c2a62993b7e1332c4c0981b3599c6b4f20d5567ba1f93207bb190a"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11260859"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7902060"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s004320000170"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027963130"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s004320000170", 
      "https://app.dimensions.ai/details/publication/pub.1027963130"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54322_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs004320000170"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s004320000170'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s004320000170'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s004320000170'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s004320000170'


 

This table displays all metadata directly associated to this object as RDF triples.

126 TRIPLES      20 PREDICATES      39 URIs      31 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s004320000170 schema:about N18bbe74fbd854eb7bf6a1f241e7455e7
2 N20dc150f42b84f39b0e5e356b570041f
3 N310c3249c5514440af59300cb18797cd
4 N33c78c5643e1483289b2b038d2642a22
5 N3fd7510a92a5420682a8d34058f15502
6 N4c797c34c66e4dbb89c234c6fcf74dad
7 N7ac72b41bb584991acb11e7f1de0a253
8 Nc3403cfeb6aa4e27a8166ecf9dfaceb8
9 Nc8d246211e87488c86a804572bcc006e
10 Ne167ad47148341638d79c28e96ec21b6
11 anzsrc-for:11
12 anzsrc-for:1112
13 schema:author N52b1dbbdd8394ae890d42f46235d5bf0
14 schema:datePublished 2001-02
15 schema:datePublishedReg 2001-02-01
16 schema:description Malignant primary adrenal tumors are rare forms of cancer with an estimated incidence of two to ten new cases per one million inhabitants per year. The 5-year survival rate for adrenocortical carcinoma is approximately 35%, whereas the 10-year survival rate of malignant pheochromocytoma reaches 40%. Clinical studies support repeated surgery as the mainstay of treatment, either with curative or palliative intention. For adrenocortical carcinoma, adjunctive treatment with oral mitotane leads to well-documented improvement of survival. Rare malignant pheochromocytomas with distant metastases are preferably treated by 131I-MIBG. Chemotherapy is reserved for unresectable tumors without sufficient response to mitotane or 131I-MIBG, respectively. Cisplatin and etoposide as single therapy, or in combination with doxorubicin or etoposide, appear to be effective in adrenocortical carcinoma. Malignant pheochromocytoma may be treated with vincristine, dacarbazine, and cyclophosphamide. Treatment with octreotide is currently being evaluated. Radiotherapy is indicated if unresectable tumor masses cause local symptoms. If symptoms of endocrine activity are not sufficiently controlled by measures aiming at tumor mass reduction, specific inhibitors of hormone synthesis or action are available. Ketoconazole is widely used for adrenocortical carcinoma, and phenoxybenzamine and metyrosine are available for malignant pheochromocytoma. This review provides guidelines for rational disease management based on still scanty clinical evidence.
17 schema:genre research_article
18 schema:inLanguage en
19 schema:isAccessibleForFree false
20 schema:isPartOf N0921a8cf78b74146aac12cb6f7c4a446
21 Nba4e9e369359446ebad365a1a9c598ab
22 sg:journal.1313647
23 schema:name Clinical management of malignant adrenal tumors
24 schema:pagination 143-155
25 schema:productId N198efac1029d4125bb4205040f7680b8
26 N2ad782a7a4cb43ebb38417080687b704
27 N496a44d3416a4076800626e5c8a14e8c
28 N73e07777e407454faa85aeee7814301d
29 Na89d25b1531243a1989e592f107039e6
30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027963130
31 https://doi.org/10.1007/s004320000170
32 schema:sdDatePublished 2019-04-11T10:19
33 schema:sdLicense https://scigraph.springernature.com/explorer/license/
34 schema:sdPublisher N982b1db3cc6d43e69420b1a8e2266b50
35 schema:url https://link.springer.com/10.1007%2Fs004320000170
36 sgo:license sg:explorer/license/
37 sgo:sdDataset articles
38 rdf:type schema:ScholarlyArticle
39 N0921a8cf78b74146aac12cb6f7c4a446 schema:volumeNumber 127
40 rdf:type schema:PublicationVolume
41 N18bbe74fbd854eb7bf6a1f241e7455e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
42 schema:name Antineoplastic Agents
43 rdf:type schema:DefinedTerm
44 N1919f7d82a564103815ae169ed31f81b rdf:first sg:person.0622641625.90
45 rdf:rest rdf:nil
46 N198efac1029d4125bb4205040f7680b8 schema:name doi
47 schema:value 10.1007/s004320000170
48 rdf:type schema:PropertyValue
49 N20dc150f42b84f39b0e5e356b570041f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
50 schema:name Adrenal Gland Neoplasms
51 rdf:type schema:DefinedTerm
52 N2ad782a7a4cb43ebb38417080687b704 schema:name pubmed_id
53 schema:value 11260859
54 rdf:type schema:PropertyValue
55 N2d3845e778464657a27cd3c859acc2e6 rdf:first sg:person.01076650120.88
56 rdf:rest N1919f7d82a564103815ae169ed31f81b
57 N310c3249c5514440af59300cb18797cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Diagnosis, Differential
59 rdf:type schema:DefinedTerm
60 N33c78c5643e1483289b2b038d2642a22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Combined Modality Therapy
62 rdf:type schema:DefinedTerm
63 N3fd7510a92a5420682a8d34058f15502 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Adrenocortical Carcinoma
65 rdf:type schema:DefinedTerm
66 N496a44d3416a4076800626e5c8a14e8c schema:name nlm_unique_id
67 schema:value 7902060
68 rdf:type schema:PropertyValue
69 N4c797c34c66e4dbb89c234c6fcf74dad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Pheochromocytoma
71 rdf:type schema:DefinedTerm
72 N52b1dbbdd8394ae890d42f46235d5bf0 rdf:first sg:person.01301252336.01
73 rdf:rest N2d3845e778464657a27cd3c859acc2e6
74 N73e07777e407454faa85aeee7814301d schema:name dimensions_id
75 schema:value pub.1027963130
76 rdf:type schema:PropertyValue
77 N7ac72b41bb584991acb11e7f1de0a253 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Antineoplastic Agents, Hormonal
79 rdf:type schema:DefinedTerm
80 N982b1db3cc6d43e69420b1a8e2266b50 schema:name Springer Nature - SN SciGraph project
81 rdf:type schema:Organization
82 Na89d25b1531243a1989e592f107039e6 schema:name readcube_id
83 schema:value 8534fbcad3c2a62993b7e1332c4c0981b3599c6b4f20d5567ba1f93207bb190a
84 rdf:type schema:PropertyValue
85 Nba4e9e369359446ebad365a1a9c598ab schema:issueNumber 3
86 rdf:type schema:PublicationIssue
87 Nc3403cfeb6aa4e27a8166ecf9dfaceb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Adrenal Cortex Neoplasms
89 rdf:type schema:DefinedTerm
90 Nc8d246211e87488c86a804572bcc006e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Humans
92 rdf:type schema:DefinedTerm
93 Ne167ad47148341638d79c28e96ec21b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Antineoplastic Combined Chemotherapy Protocols
95 rdf:type schema:DefinedTerm
96 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
97 schema:name Medical and Health Sciences
98 rdf:type schema:DefinedTerm
99 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
100 schema:name Oncology and Carcinogenesis
101 rdf:type schema:DefinedTerm
102 sg:journal.1313647 schema:issn 0171-5216
103 1432-1335
104 schema:name Journal of Cancer Research and Clinical Oncology
105 rdf:type schema:Periodical
106 sg:person.01076650120.88 schema:affiliation https://www.grid.ac/institutes/grid.411327.2
107 schema:familyName Goretzki
108 schema:givenName Peter E.
109 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076650120.88
110 rdf:type schema:Person
111 sg:person.01301252336.01 schema:affiliation https://www.grid.ac/institutes/grid.5807.a
112 schema:familyName Kopf
113 schema:givenName Daniel
114 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301252336.01
115 rdf:type schema:Person
116 sg:person.0622641625.90 schema:affiliation https://www.grid.ac/institutes/grid.5807.a
117 schema:familyName Lehnert
118 schema:givenName Hendrik
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622641625.90
120 rdf:type schema:Person
121 https://www.grid.ac/institutes/grid.411327.2 schema:alternateName Heinrich Heine University Düsseldorf
122 schema:name Department of Surgery, Heinrich Heine University Düsseldorf, Germany, DE
123 rdf:type schema:Organization
124 https://www.grid.ac/institutes/grid.5807.a schema:alternateName Otto-von-Guericke University Magdeburg
125 schema:name Department of Endocrinology and Metabolism, Otto von Guericke University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany Tel.: +49-391-6715445; Fax: +49-391-6715448 e-mail: hendrik.lehnert@medizin.uni-magdeburg.de, DE
126 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...